AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Liminatus Pharma (LIMN.O) saw an unusually steep decline today, dropping by 31.54% on a trading volume of 1.86 million shares. While no major fundamental news was reported, several technical indicators pointed to bearish momentum. The stock triggered both an RSI oversold and a MACD death cross — a combination typically associated with a continuation of a downtrend. The RSI entering oversold territory might signal a potential rebound, but the MACD death cross suggests a more prolonged bearish phase is in place. The absence of any bullish reversal signals like head and shoulders or double bottom suggests the market may not be positioning for a near-term bounce.
Unfortunately, no detailed order-flow data (e.g., block trading or liquidity clusters) was available for
.O. However, the massive intraday price drop on relatively high volume indicates a significant net outflow. In such cases, large institutional selling or short-covering pressure can accelerate the move, especially when liquidity is thin. The lack of support from buying interest — evidenced by the absence of a KDJ golden cross — points to a lack of conviction among market participants.Several stocks in the biotech and healthcare themes showed varied responses. While some stocks like ADNT and AXL surged by over 6%, LIMN.O plummeted. Stocks such as BH and ALSN gained 3–4%, indicating a broader sectoral trend of rotation into more fundamentally driven names. This divergence suggests that LIMN.O was hit by either specific selling pressure or a lack of follow-through on recent accumulation, rather than a broad sector selloff.
Knowing stock market today at a glance

Dec.04 2025

Dec.04 2025

Dec.04 2025

Dec.04 2025

Dec.04 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet